Fan Zaijing, Shou Lihong
Clinical Laboratory, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, The Fifth School of Clinical Medicine Zhejiang Chinese Medical University, Huzhou, Zhejiang, China.
Department of Hematology, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, The Fifth School of Clinical Medicine Zhejiang Chinese Medical University, No. 1558, North Sanhuan Road, Huzhou, Zhejiang 313000, China.
Ther Adv Hematol. 2023 Nov 10;14:20406207231208973. doi: 10.1177/20406207231208973. eCollection 2023.
The systemic immune-inflammation index (SII) represents the immunoinflammatory score and can be considered as a prognostic marker; however, its relevance to the prognosis in patients with diffuse large B-cell lymphoma (DLBCL) remains unclear.
The present meta-analysis was conducted to comprehensively evaluate the relationship between the SII and prognosis in patients with DLBCL.
This meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.
The PubMed, Web of Science, Embase, and Cochrane Library databases were comprehensively searched from inception to 16 March 2023. We calculated combined hazard ratios (HRs) and 95% confidence intervals (CIs) to estimate the prognostic significance of the SII for overall survival (OS) and progression-free survival (PFS) in DLBCL. In addition, this study determined odds ratios (ORs) and their 95% CIs to evaluate the correlation of SII with the clinicopathological features of DLBCL.
Five articles including 592 cases were enrolled in the current meta-analysis. According to our combined findings, the higher SII significantly predicted worse OS (HR = 3.87, 95% CI: 2.48-6.04, < 0.001) together with inferior PFS (HR = 2.38, 95% CI: 1.12-5.08, = 0.024) in DLBCL. Furthermore, a high SII was significantly correlated with B symptoms (OR = 2.52, 95% CI: 1.66-3.81, < 0.001), III-IV Ann Arbor stage (OR = 2.86, 95% CI: 1.84-4.45, < 0.001), high-intermediate/high National Comprehensive Cancer Network International Prognostic Index (OR = 2.25, 95% CI: 1.52-3.31, < 0.001), increased neutrophil-to-lymphocyte ratio (OR = 33.76, 95% CI: 17.18-66.35, < 0.001), and increased platelet-to-lymphocyte ratio (OR = 44.65, 95% CI: 5.80-343.59, < 0.001). Nonetheless, the SII was not significantly related to sex, age, lactic dehydrogenase level, Eastern Cooperative Oncology Group performance status, or histology.
According to this meta-analysis, the higher SII dramatically predicted inferior OS and PFS of DLBCL. Furthermore, an increased SII significantly correlated with some clinicopathological features representing the disease progression of DLBCL.
The protocol was registered in INPLASY under the number INPLASY202380106.
全身免疫炎症指数（SII）代表免疫炎症评分，可被视为一种预后标志物；然而，其与弥漫性大B细胞淋巴瘤（DLBCL）患者预后的相关性仍不清楚。
进行本荟萃分析以全面评估SII与DLBCL患者预后之间的关系。
本荟萃分析按照系统评价和荟萃分析的首选报告项目声明进行。
全面检索了PubMed、Web of Science、Embase和Cochrane图书馆数据库，检索时间从建库至2023年3月16日。我们计算合并风险比（HR）和95%置信区间（CI），以估计SII对DLBCL总生存期（OS）和无进展生存期（PFS）的预后意义。此外，本研究确定比值比（OR）及其95%CI，以评估SII与DLBCL临床病理特征的相关性。
本荟萃分析纳入了5篇文章，共592例病例。根据我们的综合研究结果，较高的SII显著预测DLBCL患者较差的OS（HR = 3.87，95%CI：2.48 - 6.04，P < 0.001）以及较差的PFS（HR = 2.38，95%CI：1.12 - 5.08，P = 0.024）。此外，高SII与B症状显著相关（OR = 2.52，95%CI：1.66 - 3.81，P < 0.001）、Ann Arbor分期III - IV期（OR = 2.86，95%CI：1.84 - 4.45，P < 0.001）、高中/高国际预后指数（OR = 2.25，95%CI：1.52 - 3.31，P < 0.001）、中性粒细胞与淋巴细胞比值升高（OR = 33.76，95%CI：17.18 - 66.35，P < 0.001）以及血小板与淋巴细胞比值升高（OR = 44.65，95%CI：5.80 - 343.59，P < 0.001）。然而，SII与性别、年龄、乳酸脱氢酶水平、东部肿瘤协作组体能状态或组织学无显著相关性。
根据本荟萃分析，较高的SII显著预测DLBCL患者较差的OS和PFS。此外，SII升高与一些代表DLBCL疾病进展的临床病理特征显著相关。
该方案已在INPLASY注册，注册号为INPLASY202380106。
